| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8211341 | International Journal of Radiation Oncology*Biology*Physics | 2018 | 9 Pages |
Abstract
The safety of GC4419 concurrently with chemoradiation for OCC was acceptable. Toxicities included nausea/vomiting and paresthesia. Doses of 30 and 90Â mg/d administered for 7Â weeks were selected for further study. In an exploratory analysis, severe OM seemed less frequent and briefer than expected.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Carryn M. MD, Stephen T. DMD, DMSc, Christopher M. MD, Douglas MD, Bryan G. MD, PhD, Wenqing MD, PhD, Sanjiv S. MD, Madhavi L. MD, Yuhchyau MD, PhD, Weining MD, Diane R. PhD, Jon T. MD, Jeffrey M. BS, John M. MD,